Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAT 8001

Next Previous
Drug Profile

BAT 8001

Alternative Names: Anti-ErbB2 antibody drug conjugate - Bio-Thera Solutions; Anti-HER2 antibody drug conjugate - Bio-Thera Solutions; BAT-8001

Latest Information Update: 28 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bio-Thera Solutions
  • Class Antineoplastics; Biological toxins; Drug conjugates; Immunoconjugates; Maytansinoids
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase I/II Solid tumours
  • No development reported Gastric cancer

Most Recent Events

  • 28 Dec 2022 No recent reports of development identified for preclinical development in Gastric-cancer in China (IV, Injection)
  • 28 Jul 2020 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in China (IV, Infusion)
  • 10 Dec 2019 Updated efficacy and adverse events data from a phase I trial in Breast Cancer presented at the 42nd Annual San Antonio Breast Cancer Symposium (SABCS-2019)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top